A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Adept Neuro Reaches Key Milestone in the Development of Novel Intracerebral Stereoelectroencephalography Electrodes

Adept Neuro SA (Lausanne, Switzerland), a joint venture of DIXI Medical (Le Locle, Switzerland, and Besançon, France) and Aleva Neurotherapeutics SA (Lausanne, Switzerland) developing a new generation of intracerebral stereoelectroencephalography (SEEG) electrodes facilitating localization and thermocoagulation of the epileptogenic zones, today announced that it has reached a significant milestone in the development of MEMS-enabled smart SEEGs electrodes.

MEMS are micro-electro-mechanical systems allowing for miniaturization and great flexibility of design.

DIXI Medical will be investing its second tranche into Adept Neuro well ahead of the previously scheduled date, as per its development agreement. DIXI Medical is now targeting regulatory certifications, both in the US and the EU. It expects to have its new product generation on the US market in H1’2022 and a follow-up product with enhanced sensing capabilities that will be a game-changer for practitioners and patients by H2’2023.

“We are impressed how far we have come in the past 24 months and are pleased to switch our collaboration into higher gear with this next investment tranche, said Frederic Koehn, CEO of DIXI Medical. “We have been equally impressed with what Adept’s MEMS technology can do in providing new product features and capabilities for our existing customers. Dixi is continuing to invest into new manufacturing and supply infrastructure in order to be ready for the commercial-scale production of SEEGs electrodes for drug-refractory epilepsy patients.

Dr. Andre Mercanzini, Founder of Aleva Neurotherapeutics and Executive Chairman of Adept Neuro, added: “Our team at Adept has been moving quickly and we are well ahead of our own optimistic expectations. Dixi has been a formidable partner, and their existing sales channel and loyal customer base ensures a rapid uptake of our innovative SEEGs solutions. Furthermore, Dixi’s manufacturing base has been able to quickly absorb the advantages of MEMS technology on their assembly lines, which further ensures quality and time to market for the technology.” 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy